权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of Protein Biomarkers in Post-DRE Urine for use in Liquid Biopsy of Prostate Cancer

DRE 后尿液中蛋白质生物标志物的开发用于前列腺癌液体活检

基本信息

批准号：
10261032
负责人：
Paul Christopher Boutros
金额：
$ 22万
依托单位：
EASTERN VIRGINIA MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-09-15 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10261032
关键词：
Address Adult African American Biological Markers Biopsy Cancer Patient Caucasians Cessation of life Clinical Clinical Management Consensus Data Detection Development Diagnosis Disease Disease Management Early Detection Research Network Early Diagnosis European Frequencies Gleason Grade for Prostate Cancer Health Heterogeneity Incidence Indolent Knowledge Life Local Therapy Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of pancreas Malignant neoplasm of prostate Malignant neoplasm of thyroid Morbidity - disease rate Newly Diagnosed Operative Surgical Procedures PSA screening PTEN gene Pathology Patients Population Prognosis Prostate-Specific Antigen Prostatic Neoplasms Proteome Proteomics Protocols documentation Relapse Research Resected Resources Risk Risk Assessment Risk Management Screening for Prostate Cancer Sepsis Serum Specificity Structure of base of prostate Testing Time Tissues Urine Work base biobank biomarker development burden of illness cancer biomarkers cancer risk cancer type clinical heterogeneity clinical risk cohort cost data resource digital disorder risk high risk improved liquid biopsy man men mortality novel novel marker parent grant prostate biopsy prostate cancer risk protein biomarkers recruit rectal risk stratification routine screening tool tumor urinary

项目摘要

Prostate cancer is a major and growing health problem. Prostate cancer is distinguished from almost every other adult cancer by its remarkable clinical heterogeneity. While some cancer types are almost universally curable (e.g. thyroid cancer), and others are almost universally lethal (e.g. pancreatic cancer), prostate cancers are characterized by their variability. Prostate specific antigen (PSA) is used to screen for prostate cancer, and the introduction of PSA screening detected more low risk cancers than in the “pre-PSA” era. About 40% of newly diagnosed prostate cancers are indolent and will not cause significant health problems during a man’s life. However, the remainder range from intermediate to high risk, and despite definitive local therapy about 10-20% will end up progressing to more aggressive disease. Thus, the key clinical problem in prostate cancer is not early detection of disease, but rather early detection of aggressive disease. African American (AA) men have a significantly higher incidence of prostate cancer overall, along with elevated rates of relapse after definitive local therapy and disease-specific mortality. AA men with low-risk disease who opt for surgery have almost twice the rate of upgrading, and increased frequency of adverse pathologies. These findings have led to a reluctance to recruit AA men onto active surveillance due to concern for presence of aggressive disease. It is also clear that current tissue-based prostate cancer biomarkers perform differently in AA men relative to men of European Ancestry (EA). For example, PTEN loss and ERG expression is less frequent in prostate tumors arising in AA men. It is a general consensus that with the appropriate biomarkers current clinical management strategies can be tailored to achieve ancestral equity. We hypothesize that non-invasive biomarkers developed in men of Caucasian ancestry will not be equally effective in men of AA ancestry and dedicated biomarker development strategies will improve prognosis of AA patients

前列腺癌是一个主要的和日益严重的健康问题。前列腺癌是区别于几乎所有其他成年人癌症具有显著的临床异质性虽然有些癌症类型几乎是普遍可治愈的（如甲状腺癌），癌症），并且其他几乎普遍致命（例如胰腺癌），前列腺癌的特征在于它们的可变性前列腺特异性抗原（PSA）是用来筛查前列腺癌的，而PSA筛查的引入检测到的低风险癌症比“PSA前”时代更多。大约40%的新诊断的前列腺癌是懒惰，不会在人的一生中造成重大的健康问题。然而，其余的范围从中到高风险，尽管有明确的局部治疗，约10-20%的患者最终会进展到更多侵袭性疾病因此，前列腺癌的关键临床问题不是疾病的早期发现，而是早期诊断。检测侵袭性疾病。非裔美国人（AA）男性前列腺癌的发病率明显较高总体而言，沿着确定性局部治疗后复发率和疾病特异性死亡率的升高。AA男人低风险疾病谁选择手术几乎有两倍的升级率，并增加了不良反应的频率，病理学这些发现导致不愿意招募AA男性进行主动监测，因为担心存在侵袭性疾病。同样清楚的是，目前基于组织的前列腺癌生物标志物表现不同在AA男性相对于欧洲男性（EA）。例如，PTEN缺失和ERG表达较不常见， AA男性前列腺肿瘤的发病率普遍的共识是，使用适当的生物标志物，可以调整管理战略，以实现祖传的公平。我们假设非侵入性生物标记物在高加索血统男性中开发的生物标记物在AA血统男性中不会同样有效，发展策略将改善AA患者的预后